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ScienceDirectWith 2 million people newly infected with HIV-1 in 2014, an
effective HIV-1 vaccine remains a major public health priority.
HIV-1 vaccine efficacy trials in humans, complemented by active
and passive immunization studies in non-human primates, have
identified several key vaccine-induced immunological
responses that may correlate with protection against HIV-1
infection. Potential correlates of protection in these studies
include V2-specific, polyfunctional, and broadly neutralizing
antibody responses, as well as effector memory T cell
responses. Here we review how these correlates of protection
are guiding current approaches to HIV-1 vaccine development.
These approaches include improvements on the ALVAC-HIV/
AIDSVAX B/E vaccine regimen used in the RV144 clinical trial in
Thailand, adenovirus serotype 26 vectors with gp140 boosting,
intravenous infusions of bNAbs, and replicating viral vectors.
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Introduction
Over three decades after the discovery of human immu-
nodeficiency virus type 1 (HIV-1), a vaccine remains
elusive. Variable adherence to combination antiretroviral
therapy (cART), limited drug availability, and poor in-
frastructure are some of the public health roadblocks that
show that an HIV-1 vaccine is still needed [1–3]. While
cART has resulted in dramatic progress in the treatment
of HIV-1 [4], the virus persists in a viral reservoir that is
established early in acute infection [5–8], suggesting that
there is only a short timeframe within which a vaccine has
to be effective. Moreover, enormous HIV-1 diversity
makes the design of a successful global vaccine challeng-
ing [9–11]. Nevertheless, recent preclinical and clinicalwww.sciencedirect.com vaccine studies have identified several vaccine-induced
immune responses that appear to correlate with protec-
tion against infection [12,13–15]. Although these corre-
lates of protection are statistical associations at the
present time and may or may not be causal mechanisms
of protection [16], they serve as essential guideposts on
the pathway of HIV-1 vaccine development and provide
scientific hypotheses that the next generation of HIV-1
vaccines will test.
In this review article, we provide an overview of the
current HIV-1 vaccine clinical trial landscape, focusing
on immune correlates of protection and trials that are
underway or in the pipeline. We begin by providing a
brief summary of HIV-1 vaccine clinical development
from the first efficacy trial, launched in 1998, to the
present (Table 1). We then describe several current
approaches in HIV-1 vaccine development, each of which
is focused on eliciting a different immune response based
on immune correlates of protection (Table 2, Figure 1).
The first of these approaches is aimed at generating
antibody responses specific to the V2 region of the
HIV-1 Env protein, with a canarypox viral vector and
the Env protein gp120 [17]. The second approach is
aimed at generating polyfunctional Env-specific antibody
responses, with adenovirus serotype 26 (Ad26) and/or
modified vaccinia Ankara (MVA) viral vectors, mosaic
HIV-1 sequences, and the Env protein gp140 [18–20].
The third approach is aimed at generating or delivering
broadly neutralizing antibodies (bNAbs), exemplified by
passive infusion of the CD4-binding site monoclonal
antibody (mAb) VRC01 [21,22]. The fourth approach is
aimed at generating effector memory T cell responses
with the use of live, replicating viral vectors, exemplified
by cytomegalovirus vectors.
HIV-1 vaccine clinical development: 1998 —
present
To date there have been only 6 HIV-1 vaccine candidates
that have reached efficacy trials (Table 1). The early
VAX003 and VAX004 trials used the Env subunit protein
gp120 to induce immune responses, but the vaccines did
not elicit neutralizing antibodies and failed to show
efficacy [23–26]. The focus subsequently shifted towards
vaccine strategies aimed at inducing cellular immune
responses, owing to the prominent role of CD8+ T cell
responses in control of HIV-1 replication [27,28]. The
Step study (HVTN 502) was the first efficacy trial that
focused on cell-mediated immunity using an adenovirus
serotype 5 (Ad5) viral vector to express HIV-1 Gag, Pol,Current Opinion in Immunology 2016, 41:39–46
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Table 1
Completed HIV-1 vaccine efficacy trials
Trial Vaccine description Immune responses
observed
Efficacy outcome
VAX004 AIDSVAX B/B gp120 (MN
and GNE8 subtype B) gp120
in alum
Non-neutralizing antibody
response; ADCVI
No efficacy
VAX003 AIDSVAX B/E gp120
(subtype B MN and
CRF01_AE CM244) gp120 in
alum
Non-neutralizing antibody
response
No efficacy
HVTN 502/Step Trial Adenovirus type 5 Clade B
gag/pol/nef
HIV-1 specific CD4+ and
CD8+ responses
No efficacy, increased
infection risk
HVTN 503 (Phambili trial) Adenovirus type 5 Clade B
gag/pol/nef
HIV-1 specific CD4+ and
CD8+ responses
No efficacy, increased
infection risk
RV144 ALVAC-HIV (recombinant
canarypox vector)/vCP1521
and AIDSVAX B/E rgp120 in
alum
Humoral and cellular immune
responses; Non-neutralizing
Ab to V1V2*, high ADCC,
HIV-1 specific IgG3, FcgRIIC
receptor
* Correlate of protection
31.2% efficacy at 42 months,
60% efficacy at 12 months
HVTN 505 DNA Gag, Pol, and Nef from
HIV-1 subtype B and Env
from subtypes A, B, and C,
and rAd5 subtype B Gag-Pol
and Env A, B, and C
T-cell responses to HIV-1
potential T-cell epitopes;
CD4+ HIV Gag responses
No efficacy
HVTN, HIV Vaccine Trials Network; ADCVI, antibody-dependent cell-mediated virus inhibition; ADCC, antibody-dependent cellular cytotoxicity.and Nef internal proteins. The Step trial did not confer
protection against infection or induce virologic control,
and increased rates of infection were observed in a subset of
vaccinees [29,30]. The Phambili trial (HVTN 503) tested
the same vaccine used in the Step trial and also did not
reduce infection rates [31]. The only signal of efficacy of an
HIV-1 vaccine candidate was shown in the RV144 trial in
Thailand, which showed 31% efficacy with a prime-boost
regimen of a canarypox viral vector (ALVAC-HIV) and the
Env subunit protein gp120 (AIDSVAX B/E) [17]. The
HVTN 505 trial tested a multi-clade DNA prime with a
recombinant Ad5 boost designed to generate both humoral
and cellular responses, and this vaccine also did not show
efficacy [32–34]. The lessons from these trials suggest that
the global diversity of HIV-1 strains and the challenge of
inducing functional immune responses are major obstacles
to a successful HIV-1 vaccine.
Current landscape of HIV-1 vaccine clinical
research
Vaccines that elicit V2-specific antibody responses
RV144 used an ALVAC-HIV/AIDSVAX B/E regimen
based on clade B and CRF01_AE sequences that
matched the prevailing HIV-1 strains in Thailand
[17,35]. Subsequent analyses showed that non-neutraliz-
ing antibodies to variable loops 1 and 2 (V1V2) regions of
HIV-1 Env were associated with a reduced risk of HIV-1
acquisition [12,15], and a genetic sieve analysis demon-
strated that the ALVAC-HIV/AIDSVAX B/E regimen
had improved efficacy against viruses that matched the
immunogen sequence in the V2 location [15]. Moreover,Current Opinion in Immunology 2016, 41:39–46 high levels of antibody-dependent cellular cytotoxicity
(ADCC) were also shown to correlate with a reduced risk
of HIV-1 acquisition in RV144 [36] and V2-specific
monoclonal antibodies isolated from RV144 vaccines
were shown to mediate ADCC against HIV-1-infected
CD4+ T cells [37]. HIV-1 specific IgG3 responses were
also noted to correlate with protection in RV144 and
distinguish this trial from the VAX003 trial [13].
These data suggested a path forward for HIV-1 vaccine
development by raising the hypothesis that non-neutral-
izing V2-specific antibodies, particularly if well-matched
to local circulating strains, might have the potential to
block HIV-1 acquisition (Table 2, Figure 1). As a result,
multiple strategies are being pursued to build on the
RV144 findings, including:
 Changing the RV144 vaccine schedule to improve the
magnitude and durability of V2-specific antibody
responses. For example, the RV305 trial is studying
extended boosting of the ALVAC-HIV/AIDSVAX B/E
regimen in Thailand (NCT01435135).
 Transferring the RV144 regimen to a new region to test
whether the V2-specific responses generated in
Thailand might also provide protection in a different
region. The HVTN 097 trial is testing this strategy by
studying the ALVAC-HIV/AIDSVAX B/E regimen in
South Africa (NCT02109354); early data indicates
similar cellular responses as RV144 [38].
 Adapting the RV144 regimen to a different region to
test whether changing the vaccine sequences to matchwww.sciencedirect.com
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Table 2
Ongoing HIV-1 vaccine clinical trials based on known immune correlates of protection
Vaccines that elicit V2-specific antibody responses
Extended boosting of RV144 regimen ALVAC-HIV/AIDSVAX B/E in Thailand NCT01435135 U.S. Army
Testing of RV144 regimen in new region ALVAC-HIV, AIDSVAX B/E in South Africa NCT02109354 HVTN
Adapting RV144 regimen to new region ALVAC-HIV (vCP2438), bivalent Subtype
C/MF59 in South Africa
NCT02404311 NIAID
Changing RV144 adjuvants ALVAC/gp120 with Alum vs. MF59
ALVAC/gp120
Planned
Planned
HVTN
HVTN
Vaccines that elicit polyfunctional antibody responses
Novel Vaccine regimens based on Ad26 vector,
mosaic immunogens, and gp140 protein
Ad26.Mos.HIV/MVA-Mosaic/gp140
Ad26.Mos.HIV/Clade C gp140
MVA-Mosaic
Clade C gp140
NCT02315703
NCT02685020
NCT02218125
NCT02304185
Crucell Holland BV
Crucell Holland BV
Crucell Holland BV
Crucell Holland BV
Efforts that elicit (or deliver) broadly neutralizing antibodies
Passive infusion of bNAbs VRC01
VRC01
VRC01LS
VRC01 efficacy
10-1074
NCT02256631
NCT02568215
NCT02599896
Planned
NCT02511990
NIAID
NIAID
NIAID
Rockefeller Univ.
bNAb epitope scaffolds None yet
B cell lineage design None yet
Gene delivery rAAV1-PG9DP NCT01937455 IAVI
Vaccines that elicit effector memory T cells at mucosal sites of infection
Replicating vectors VSV-Indiana HIV Gag
rVSV HIV Gag
Ad4-mgag, Ad4-EnvC150
rcAd26.MOS1.HIV-Env
HCMV/HIV
NCT01438606
NCT01578889
NCT01989533
NCT02366013
Planned
NIAID
NIAID
NIAID
IAVI
HVTN, HIV Vaccine Trials Network; NIAID, National Institute of Allergy and Infectious Diseases; IAVI, International AIDS Vaccine Institute.local prevailing strains will generate regional V2-
specific responses. The HVTN 100 trial is pursuing
this strategy with testing of an ALVAC-HIV
(vCP2438)/bivalent subtype C gp120/MF59 regimen
in South Africa (NCT02404311), with plans to move to
efficacy testing in the HVTN 702 trial [39].
 Using different adjuvants to the RV144 regimen to
enhance immune responses [40–42]. For example,
HVTN 107 is a planned phase1/2a study in Zimbabwe
comparing ALVAC-HIV (vCP2438)/bivalent subtype
C gp120 with either MF59 or aluminum hydroxide
[43].
Vaccines that elicit polyfunctional antibody responses
The modest and transient vaccine efficacy observed in
the RV144 trial has also inspired efforts to push forward
with additional vaccine concepts. Polyfunctional Env-
specific antibody responses were associated with a signif-
icantly reduced risk of simian-human immunodeficiency
virus (SHIV) and simian immunodeficiency virus (SIV)
acquisition following repetitive rectal challenges in vac-
cinated nonhuman primates [44]. Specifically, we
showed that rhesus monkeys primed with Ad26 vectors
expressing SIVsmE543 Env, Gag, and Pol and boosted
with adjuvanted SIVmac32H Env gp140 demonstrated
complete protection in 50% of vaccinated animals against
a series of repeated, heterologous, intrarectal SIVmac251
challenges that infected all controls. Analysis of antibodywww.sciencedirect.com Fc functions, including ADCC, antibody-dependent cel-
lular phagocytosis (ADCP), antibody-dependent natural
killer (NK) cell activities (ADNKA), antibody-dependent
complement deposition (ADCD), and glycosylation pro-
files, revealed that the protein boost resulted in a more
polyfunctional antibody response that also correlated with
protective efficacy. These data supported the results of
earlier vaccine studies in non-human primates that also
demonstrated that non-neutralizing antibody effector
functions correlated with protective efficacy [45,46].
Novel Adenovirus serotype 26 vectors are thus being
evaluated in clinical studies in combination with the
Env trimeric protein gp140. In initial studies, an Ad26
vector expressing a clade A HIV-1 Env immunogen
(Ad26.EnvA.01) was shown to be safe, well-tolerated,
and immunogenic in three completed clinical trials
(NCT00618605, NCT01103687, and NCT01215149).
Ad26 vectors have been shown in multiple models to
be biologically distinct from Ad5 [47], the vector used in
the Step study. Ad26 has also been shown to elicit
polyfunctional antibody responses in humans using sys-
tems serology [48]. This platform characterized Fc-ef-
fector functions, ADCC, ADCP, NK cell IFN-g
secretion, NK MIP-1b secretion, and NK CD107a acti-
vation as well as multiple other biophysical measure-
ments [48]. Using this platform, Chung et al.
demonstrated that Ad26.EnvA.01 elicited a network ofCurrent Opinion in Immunology 2016, 41:39–46
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Figure 1
Potential Correlates of Protection for Ongoing HIV Vaccine Studies
V1V2-Specific and/or Polyfunctional
Non-neutralizing Antibodies
Broadly Neutralizing
Antibodies
Effector Memory
T-cells at Mucosal Sites
ADCP
HIV+ CD4
T-Cell
ADCC
Complement
Activation
NnAB
nAb
Envelope
Glycoprotein
Memory T-cells
NK cell
Phagocyte
Current Opinion in Immunology
Potential correlates of protection for ongoing HIV vaccine studies. (1) V1V2-specific and/or polyfunctional non-neutralizing antibodies (NnAb, left
panel). The cartoon represents the mechanism by which non-neutralizing antibodies may bind to infected CD4+ T cells, triggering complement
activation, antibody-dependent cellular phagocytosis (ADCP), and/or antibody-dependent cellular cytotoxicity (ADCC). (2) Broadly neutralizing
antibodies (nAb, middle panel). The cartoon represents neutralization of the infecting virus via binding to the Envelope glycoprotein. (c) Effector
memory T-cells at mucosal sites (right panel). The cartoon depicts continuous antigen stimulation via an effector memory T-cell pool.antibody functions and Fc-receptor binding activity that
was clearly distinguished from responses elicited by the
RV144, VAX003/004, and Step regimens.
Multivalent Ad26 vectors have recently been developed
that express mosaic immunogens (Ad26.Mos.HIV) with
the goal of generating polyfunctional antibodies and di-
verse cellular immune responses that recognize HIV-1
epitopes from global viruses. Mosaic HIV-1 Env, Gag,
and Pol sequences are bioinformatically designed to opti-
mize coverage of global HIV-1 diversity [49–52], and have
been shown to expand cellular and humoral immune
responses in non-human primates when expressed by
adenoviral vectors [44,53–55]. The clinical trial HIV-V-
A004/IPCAVD009 (NCT02315703) launched in 2015, is
evaluating Ad26.Mos.HIV, MVA vectors expressing the
same mosaic antigens (MVA-mosaic) and a clade C gp140
boost. This study is sponsored by Crucell Holland B.V.
(Janssen Pharmaceuticals), and has completed enrollment
of 400 subjects in Rwanda, South Africa, Thailand,
Uganda, and the USA. The MVA-mosaic vaccine was also
evaluated in a phase 1 clinical trial, HIV-V-A002/
IPCAVD006, that launched in 2014; this study is examin-
ing two injections of MVA-mosaic in unvaccinated healthy
individuals and individuals who previously received the
Ad26.EnvA.01 vaccine (NCT02218125) [18,19]. A third
vaccine trial of mosaic immunogens is launching inCurrent Opinion in Immunology 2016, 41:39–46 2016 and is testing Ad26.Mos.HIV and clade C gp140
using shorter vaccine schedules (HPX1002/IPCAVD
010; NCT02685020).
Finally, Env gp140 protein subunit immunogens are also
undergoing clinical testing as part of multi-component
vaccine regimens to elicit polyfunctional antibodies. For
example, the South African AIDS Vaccine Initiative
(SAAVI) has begun testing of a Novartis subtype C
gp140 boost in the context of a previous DNA/MVA/
truncated gp160 vaccine (HVTN 073, NCT01423825
and HVTN 073E, NCT01423825). As mentioned above,
a clade C gp140 trimeric protein is also being tested in the
HIV-V-A003/IPCAVD008 (NCT02304185), HIV-V-A004/
IPCAVD009, and HPX1002/IPCAVD010 studies.
Efforts to elicit (or deliver) broadly neutralizing
antibodies
One of the unachieved goals in HIV-1 vaccine develop-
ment is the generation of immunogens that can elicit
broadly neutralizing antibodies (bNAbs) [56–58]. Such
bNAbs are found in about 10–30% of infected people and
develop several years after infection [59]. The sole target
of these antibodies is the Env glycoprotein, a highly
diverse structure with glycosylation patterns that hide
many of the potential neutralizing antibody targets
[60,61]. Several broad and potent mAbs have shownwww.sciencedirect.com
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mates. PGT121, which targets a glycan-dependent site
on the V3 loop of Env, elicited sterilizing immunity in
macaques against SHIV infection at low doses of 1–5 mg/
kg [62]. Other antibodies, including VRC01, 2F5, 2G12,
b12, 4E10, 3BNC117, 10-1074, and others also elicited
protection against SHIV challenge in non-human pri-
mates in combination or at higher doses [63–67].
Multiple approaches are being pursued to elicit bNAbs by
immunization. One approach consists of designing immu-
nogens that better mimic bNAb epitopes, for example,
novel native-like Env trimeric proteins such as BG505
SOSIP.664 or bNAb epitope mimics on scaffolds [68–71].
Another approach is to use immunogens that bind germ-
line precursors of bNAbs and thus stimulate different
stages of the bNAb clonal lineage and allow for evolution
of B-cells to production of bNAb, known as B-cell lineage
vaccines [72].
Another option for the delivery of bNAbs is gene
transfer, which is sometimes referred to as vectored
immunoprophylaxis. Adeno-associated virus (AAV) vec-
tors are being used for this task to enable the direct
expression of bNAbs. SIV modified immunoadhesins
expressed via AAVs showed protection and long term
neutralization in a non-human primate study [73]. AAVs
have also been used to induce lifelong mAb production in
humanized mice, affording protection against HIV [74].
Another immunoadhesin, CD4-Ig was combined with a
modified CCR5 binding peptide without inhibiting hydro-
phobic residues to enhance Env binding. This combina-
tion was expressed for up to 10 months in non-human
primates and showed protection against SHIV challenge
[75]. One AAV delivering the neutralizing antibody PG9 is
currently being tested in a phase I study (NCT01937455).
Vaccine strategies to induce bNAbs are in their early stages
in terms of clinical development and a full review of
strategies to induce bNAbs is beyond the scope of this
review. Efforts to administer bNAbs passively are therefore
being pursued in proof-of-concept studies to establish
whether bNAbs protect against HIV-1 infection in
humans. The first bNAb to begin human clinical trials is
VCR-HIVMAB060-00-AB (VRC01), which targets the
CD4 binding site. VRC01 neutralizes an extensive global
panel of Env-pseudotyped viral strains in vitro [22,76,77],
and passive transfer of VRC01 along with two other bNAbs
10E8 and PG9 showed complete protection against SHIV
challenge in rhesus macaques [67]. Thus far, VRC01 has
been shown to be safe and well-tolerated, and to suppress
viral replication transiently in HIV-1-infected individuals
in the Phase 1 clinical trials VRC601 and VRC602 [78,79].
A phase 2b safety and efficacy study of VRC01 has recently
begun and early phase clinical trials of other bNAbs are
underway (NCT02256631; NCT02568215 (HVTN 703);
NCT02599896 (VRC606)).www.sciencedirect.com Vaccines that elicit effector memory T cells at mucosal
sites of infection
The HIV-1 vaccine strategies discussed above aim to
elicit humoral immune responses — V2-specific, poly-
functional, and broadly neutralizing antibodies — as
these responses may correlate with reduced risk of
HIV-1 acquisition. Data from non-human primates also
suggests that replicating viral vectors may elicit cellular
immune responses that can prevent systemic HIV-1
infection by limiting the spread of mucosally acquired
infection. For example, a rhesus cytomegalovirus
(RhCMV) vector expressing SIV antigens elicited SIV-
specific effector-memory T cells responses at mucosal
sites of infection [80], prevented systemic, progressive
dissemination of infection [81], and led to control of
viremia and pathogenesis against SIVmac239 in rhesus
macaques [82]. Such an approach suggests that the
RhCMV vector established a persistent HIV-1 effector
T-cell pool that could rapidly control viral replication at
the time of infection.
Several replicating vectors are being explored for their
ability to induce persistent immune responses via contin-
uous antigen stimulation, especially at mucosal sites of
potential infection. The hypothesis is that these immune
responses may inhibit viral infection prior to establish-
ment of a viral reservoir and diversification of the infect-
ing virus, thus containing or aborting early infection. In
addition to modified attenuated human CMV vectors,
which are not yet in clinical trials [82], replicating
adenoviruses (Ad) are also being explored, as they persist
in mucosal sites [83]. For example, mucosal IgA titers
following immunization with a replicating Ad-SIV vac-
cine in macaques correlated with improved control of
viremia [84]. Clinical advancement of replicating Ad
vectors is underway with replication-competent recom-
binant adenovirus serotype 4 (Ad4) HIV-1 vaccine regi-
mens (Ad4-mgag and Ad4-EnvC150); a phase 1 clinical
trial testing the oral and intranasal routes of administra-
tion is currently underway (NCT01989533). In addition,
an oral replicating adenovirus serotype 26 (Ad26) vector
expressing HIV-1 Env is also in Phase 1 testing
(NCT02366013) [85]. Additionally, the vesicular stoma-
titis virus (VSV) vector has entered phase 1 clinical
testing (NCT01438606) [86], and plans are in place to
conduct a follow-up trial using a DNA prime-VSV vector
boost (NCT01578889).
Conclusions
An HIV-1 vaccine has been a daunting challenge due to
global HIV-1 diversity and the difficulties in inducing
protective antibody responses and cellular immune
responses. Here we discuss four current approaches to
the development of a successful HIV-1 vaccine, each
based on different immune correlates of protection.
The first approach is to develop vaccines that elicit V2-
specific antibody responses and that are well matched toCurrent Opinion in Immunology 2016, 41:39–46
44 Vaccineslocally circulating strains. Examples of this approach
include efforts to build on the ALVAC/AIDSVAX B/E
vaccine regimens tested in RV144 with ongoing clinical
trials in Thailand and Africa. The second approach is to
develop vaccines to elicit diverse, polyfunctional anti-
body responses. Examples of this approach include efforts
to test Ad26 vectors, mosaic immunogens, and trimeric
gp140 protein regimens. The third approach is to elicit (or
deliver) broadly neutralizing antibodies through immuni-
zation, gene delivery, or passive administration. The
fourth strategy is to elicit effector memory T cells through
the use of replicating vectors. As all four of these
approaches move towards efficacy trials, the field will
have an unprecedented opportunity to test prospectively
which immune correlates are confirmed and afford pro-
tection against HIV-1 in humans.
Acknowledgements
We acknowledge support from the National Institutes of Health (AI060354
(K.E.S.); AI095985, AI096040, AI100663, AI124377, OD011170 (D.H.B.)),
the Bill and Melinda Gates Foundation, and the Ragon Institute of MGH,
MIT, and Harvard.
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Fox MP, Rosen S: Retention of adult patients on antiretroviral
therapy in low- and middle-income countries. JAIDS J Acquir
Immune Defic Syndr 2015, 69:98-108.
2. Schaecher KL: The importance of treatment adherence in HIV.
Am J Manage Care 2013, 19 s231–7.
3. Obiako OR, Muktar HM: Challenges of HIV treatment in
resource-poor countries: a review. Niger J Med 2010,
19:361-368.
4. AIDS by the numbers 2015 j UNAIDS. 2015.
5. Barouch DH, Deeks SG: Immunologic strategies for HIV-1
remission and eradication. Science 2014, 345:169-174.
6. Chun T-W, Justement JS, Murray D, Hallahan CW, Maenza J,
Collier AC, Sheth PM, Kaul R, Ostrowski M, Moir S et al.: Rebound
of plasma viremia following cessation of antiretroviral therapy
despite profoundly low levels of HIV reservoir: implications for
eradication. AIDS 2010, 24:2803-2808.
7. Chun T-W, Moir S, Fauci AS: HIV reservoirs as obstacles and
opportunities for an HIV cure. Nat Immunol 2015, 16:584-589.
8. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D:
Cell-to-cell spread of HIV permits ongoing replication despite
antiretroviral therapy. Nature 2011, 477:95-98.
9. Hemelaar J: The origin and diversity of the HIV-1 pandemic.
Trends Mol Med 2012, 18:182-192.
10. Hemelaar J, Gouws E, Ghys PD, Osmanov S: Global and regional
distribution of HIV-1 genetic subtypes and recombinants in
2004. AIDS 2006, 20 W13–23.
11. Ndung’u T, Weiss RA: On HIV diversity. AIDS 2012, 26:1255-
1260.
12.

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD,
Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R et al.:
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
N Engl J Med 2012, 366:1275-1286.
This paper showed an inverse correlation between V1V2 Abs against
different HIV-1 subtypes and risk of HIV-1 infection in the RV144 trial,Current Opinion in Immunology 2016, 41:39–46 establishing a method to test V1V2 antibodies as a correlate of protection
in future vaccine trials.
13. Yates NL, Liao H-X, Fong Y, deCamp A, Vandergrift NA,
Williams WT, Alam SM, Ferrari G, Yang Z, Seaton KE et al.:
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1
infection risk and declines soon after vaccination. Sci Transl
Med 2014, 6 228ra39.
14. Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL,
Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA
et al.: Vaccine-induced IgG antibodies to V1V2 regions of
multiple HIV-1 subtypes correlate with decreased risk of HIV-1
infection. PLOS ONE 2014, 9:e87572.
15. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-
Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA
et al.: Increased HIV-1 vaccine efficacy against viruses with
genetic signatures in Env V2. Nature 2012, 490:417-420.
16. Plotkin SA, Gilbert PB: Nomenclature for immune correlates of
protection after vaccination. Clin Infect Dis 2012, 54:1615-1617.
17. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J,
Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E,
Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP,
Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C,
Thongcharoen P, Rob M-TI: Vaccination with ALVAC and
AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med
2009, 361:2209-2220.
18. Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP,
Kleinjan JA, Gothing JA, Engelson BA, Carey BR, Oza A et al.:
First-in-human evaluation of a hexon chimeric adenovirus
vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis 2014,
210:1052-1061.
19. Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A,
Alter G, Chung A, Dugast A-S, Frahm N et al.: Characterization of
humoral and cellular immune responses elicited by a
recombinant adenovirus serotype 26 HIV-1 Env vaccine in
healthy adults (IPCAVD 001). J Infect Dis 2013, 207:248-256.
20. Nkolola JP, Bricault CA, Cheung A, Shields J, Perry J, Kovacs JM,
Giorgi E, van Winsen M, Apetri A, Brinkman-van der Linden ECM
et al.: Characterization and immunogenicity of a novel mosaic
M HIV-1 gp140 trimer. J Virol 2014, 88:9538-9552.
21. Caskey M, Klein F, Lorenzi JCC, Seaman MS, West AP, Buckley N,
Kremer G, Nogueira L, Braunschweig M, Scheid JF et al.: Viraemia
suppressed in HIV-1-infected humans by broadly neutralizing
antibody 3BNC117. Nature 2015, 522:487-491.
22. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS,
Zhou T, Schmidt SD, Wu L, Xu L et al.: Rational design of
envelope identifies broadly neutralizing human monoclonal
antibodies to HIV-1. Science 2010, 329:856-861.
23. Forthal DN, Gilbert PB, Landucci G, Phan T: Recombinant gp120
vaccine-induced antibodies inhibit clinical strains of HIV-1 in
the presence of Fc receptor-bearing effector cells and
correlate inversely with HIV infection rate. J Immunol 2007,
178:6596-6603.
24. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP,
Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG et al.:
Correlation between immunologic responses to a
recombinant glycoprotein 120 vaccine and incidence of HIV-1
infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis
2005, 191:666-677.
25. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF:
Placebo-controlled phase 3 trial of a recombinant
glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis
2005, 191:654-665.
26. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van
Griensven F, Hu D, Tappero JW, Choopanya K: Randomized,
double-blind, placebo-controlled efficacy trial of a bivalent
recombinant glycoprotein 120 HIV-1 vaccine among injection
drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-
1671.
27. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN,
McCune JM, Deeks SG: HLA class I-restricted T-cell responses
may contribute to the control of human immunodeficiencywww.sciencedirect.com
New concepts in HIV-1 vaccine development Stephenson, D’Couto and Barouch 45virus infection, but such responses are not always necessary
for long-term virus control. J Virol 2008, 82:5398-5407.
28. Cao Y, Qin L, Zhang L, Safrit J, Ho DD: Virologic and
immunologic characterization of long-term survivors of
human immunodeficiency virus type 1 infection. N Engl J Med
1995, 332:201-208.
29. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R,
Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C et al.: Efficacy
assessment of a cell-mediated immunity HIV-1 vaccine (the
Step Study): a double-blind, randomised, placebo-controlled,
test-of-concept trial. Lancet 2008, 372:1881-1893.
30. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del
Rio C, Casapia M, Santiago S, Gilbert P, Corey L et al.: Extended
follow-up confirms early vaccine-enhanced risk of HIV
acquisition and demonstrates waning effect over time among
participants in a randomized trial of recombinant adenovirus
HIV vaccine (Step Study). J Infect Dis 2012, 206:258-266.
31. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker L-G,
Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH et al.:
Safety and efficacy of the HVTN 503/Phambili study of a clade-
B-based HIV-1 vaccine in South Africa: a double-blind,
randomised, placebo-controlled test-of-concept phase 2b
study. Lancet Infect Dis 2011, 11:507-515.
32. Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, Lim S-Y,
Yeh WW, Asmal M, Gelman RS, Shen L et al.: Immune
and genetic correlates of vaccine protection against
mucosal infection by SIV in monkeys. Sci Transl Med 2011, 3
81ra36.
33. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS,
Moodie Z, Grove D, Gray G, Bekker L-G, McElrath MJ et al.: A
phase IIA randomized clinical trial of a multiclade HIV-1 DNA
prime followed by a multiclade rAd5 HIV-1 vaccine boost in
healthy adults (HVTN204). PLoS ONE 2011, 6:e21225.
34. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ,
Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD
et al.: Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
N Engl J Med 2013, 369:2083-2092.
35. Excler JL, Plotkin S: The prime-boost concept applied to HIV
preventive vaccines. AIDS 1997, 11(Suppl. A) S127–37.
36. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang K-
K, Gilbert PB, Huang Y, Gurley TC, Kozink DM et al.: Antibody-
dependent cellular cytotoxicity-mediating antibodies from
an HIV-1 vaccine efficacy trial target multiple epitopes and
preferentially use the VH1 gene family. J Virol 2012,
86:11521-11532.
37. Liao H-X, Bonsignori M, Alam SM, McLellan JS, Tomaras GD,
Moody MA, Kozink DM, Hwang K-K, Chen X, Tsao C-Y et al.:
Vaccine induction of antibodies against a structurally
heterogeneous site of immune pressure within HIV-1 envelope
protein variable regions 1 and 2. Immunity 2013, 38:176-186.
38. Gray GE, Andersen-Nissen E, Grunenberg N, Huang Y, Roux S,
Laher F, Innes C, Gu N, DiazGranados C, Phogat S et al.: HVTN
097 evaluation of the RV144 vaccine regimen in HIV
uninfected South African adults. AIDS Res Hum Retroviruses
2014, 30:A33-A34.
39. O’Connell RJ, Kim JH, Corey L, Michael NL: Human
immunodeficiency virus vaccine trials. Cold Spring Harb
Perspect Med 2012, 2:007351.
40. McElrath MJ: Selection of potent immunological adjuvants for
vaccine construction. Semin Cancer Biol 1995, 6:375-385.
41. Rhee EG, Barouch DH: Translational mini-review series on
vaccines for HIV: harnessing innate immunity for HIV vaccine
development. Clin Exp Immunol 2009, 157:174-180.
42. Vaccari M, Gordon SN, Fourati S, Schifanella L, Cameron M,
Keele BF, Shen X, Tomaras G, Billings E, Rao M et al.: Adjuvant
dependent mucosal V2 responses and RAS activation in
vaccine induced protection from SIV mac251 acquisition. AIDS
Res Hum Retroviruses 2014, 30:A64-A65.
43. HVTN Studies. HVTN Ongoing Protoc.www.sciencedirect.com 44.

Barouch DH, Alter G, Broge T, Linde C, Ackerman ME, Brown EP,
Borducchi EN, Smith KM, Nkolola JP, Liu J et al.: Protective
efficacy of adenovirus/protein vaccines against SIV
challenges in rhesus monkeys. Science 2015, 349:320-324.
In this study, protective efficacy of Ad26 expressing SIVsmE453 Env/
Gag/Pol and Env gp140 correlated with polyfunctionality of Env-specific
antibody responses. The protein boost was critical to eliciting these
polyfunctional antibody responses.
45. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K,
McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS et al.:
Protective efficacy of a global HIV-1 mosaic vaccine against
heterologous SHIV challenges in rhesus monkeys. Cell 2013,
155:531-539.
46. Ackerman ME, Moldt B, Wyatt RT, Dugast A-S, McAndrew E,
Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q et al.: A
robust, high-throughput assay to determine the phagocytic
activity of clinical antibody samples. J Immunol Methods 2011,
366:8-19.
47. Barouch DH, Picker LJ: Novel vaccine vectors for HIV-1. Nat Rev
Microbiol 2014, 12:765-771.
48.

Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK,
Dunphy LJ, Suscovich TJ, Frahm N, Linde C, Mahan AE et al.:
Dissecting polyclonal vaccine-induced humoral immunity
against HIV using systems serology. Cell 2015, 163:988-998.
Systems serology is an approach to broadly characterize the non-neu-
tralizing Fc-mediated effector functions of antibodies that may correlate
with protection against infection and is a platform that could be used to
compare HIV-1 vaccines.
49. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K,
Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD et al.:
Polyvalent vaccines for optimal coverage of potential T-cell
epitopes in global HIV-1 variants. Nat Med 2007, 13:100-106.
50. Ndhlovu ZM, Piechocka-Trocha A, Vine S, McMullen A,
Koofhethile KC, Goulder PJR, Ndung’u T, Barouch DH, Walker BD:
Mosaic HIV-1 Gag antigens can be processed and presented
to human HIV-specific CD8+ T cells. J Immunol 2011, 186:6914-
6924.
51. Thurmond J, Yoon H, Kuiken C, Yusim K, Perkins S, Theiler J,
Bhattacharya T, Korber B, Fischer W: Web-based design and
evaluation of T-cell vaccine candidates. Bioinformatics 2008,
24:1639-1640.
52. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP,
Salazar MG, Chen Y, Weng Z, Weaver EA, Gao F et al.: Ancestral
and consensus envelope immunogens for HIV-1 subtype C.
Virology 2006, 352:438-449.
53. Barouch DH, O’Brien KL, Simmons NL, King SL, Abbink P,
Maxfield LF, Sun Y-H, La Porte A, Riggs AM, Lynch DM et al.:
Mosaic HIV-1 vaccines expand the breadth and depth of
cellular immune responses in rhesus monkeys. Nat Med 2010,
16:319-323.
54. Stephenson KE, SanMiguel A, Simmons NL, Smith K, Lewis MG,
Szinger JJ, Korber B, Barouch DH: Full-length HIV-1
immunogens induce greater magnitude and comparable
breadth of T lymphocyte responses to conserved HIV-1
regions compared with conserved-region-only HIV-1
immunogens in rhesus monkeys. J Virol 2012, 86:11434-11440.
55. Santra S, Muldoon M, Watson S, Buzby A, Balachandran H,
Carlson KR, Mach L, Kong W-P, McKee K, Yang Z-Y et al.:
Breadth of cellular and humoral immune responses elicited in
rhesus monkeys by multi-valent mosaic and consensus
immunogens. Virology 2012, 428:121-127.
56. Stamatatos L: HIV vaccine design: the neutralizing antibody
conundrum. Curr Opin Immunol 2012, 24:316-323.
57. Hraber P, Korber BT, Lapedes AS, Bailer RT, Seaman MS, Gao H,
Greene KM, McCutchan F, Williamson C, Kim JH et al.: Impact of
clade, geography, and age of the epidemic on HIV-1
neutralization by antibodies. J Virol 2014, 88:12623-12643.
58. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L,
Nussenzweig MC: Antibodies in HIV-1 vaccine development
and therapy. Science 2013, 341:1199-1204.Current Opinion in Immunology 2016, 41:39–46
46 Vaccines59. Stamatatos L, Morris L, Burton DR, Mascola JR: Neutralizing
antibodies generated during natural HIV-1 infection: good
news for an HIV-1 vaccine? Nat Med 2009, 15:866-870.
60. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M,
Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams M-R
et al.: Evolution of an HIV glycan-dependent broadly
neutralizing antibody epitope through immune escape. Nat
Med 2012, 18:1688-1692.
61. Klein JS, Bjorkman PJ: Few and far between: how HIV may be
evading antibody avidity. PLoS Pathog 2010, 6:e1000908.
62. Moldt B, Rakasz EG, Schultz N, Chan-Hui P-Y, Swiderek K,
Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P
et al.: Highly potent HIV-specific antibody neutralization in vitro
translates into effective protection against mucosal SHIV
challenge in vivo. Proc Natl Acad Sci U S A 2012, 109:18921-18925.
63. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D,
Louder MK, Brown CR, Sapan CV, Frankel SS et al.: Protection of
Macaques against pathogenic simian/human
immunodeficiency virus 89.6PD by passive transfer of
neutralizing antibodies. J Virol 1999, 73:4009-4018.
64. Parren PWHI, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-
Mayer C, Moore JP, Burton DR: Antibody protects macaques
against vaginal challenge with a pathogenic R5 simian/human
immunodeficiency virus at serum levels giving complete
neutralization in vitro. J Virol 2001, 75:8340-8347.
65. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL,
Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI et al.:
Broadly neutralizing monoclonal antibodies 2F5 and 4E10
directed against the human immunodeficiency virus type
1 gp41 membrane-proximal external region protect against
mucosal challenge by simian-human immunodeficiency virus
SHIVBa-L. J Virol 2010, 84:1302-1313.
66. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G,
Forthal DN, Koff WC, Watkins DI, Burton DR: Broadly neutralizing
human anti-HIV antibody 2G12 is effective in protection
against mucosal SHIV challenge even at low serum
neutralizing titers. PLoS Pathog 2009, 5:e1000433.
67. Pegu A, Yang Z, Boyington JC, Wu L, Ko S-Y, Schmidt SD,
McKee K, Kong W-P, Shi W, Chen X et al.: Neutralizing
antibodies to HIV-1 envelope protect more effectively in vivo
than those to the CD4 receptor. Sci Transl Med 2014, 6 243ra88.
68. Mann JK, Ndung’u T: HIV-1 vaccine immunogen design
strategies. Virol J 2015, 12:3.
69. Sanders RW, Derking R, Cupo A, Julien J-P, Yasmeen A, de Val N,
Kim HJ, Blattner C, de la Pen˜a AT, Korzun J et al.: A next-
generation cleaved, soluble HIV-1 Env trimer, BG505
SOSIP.664 gp140, expresses multiple epitopes for broadly
neutralizing but not non-neutralizing antibodies. PLoS Pathog
2013, 9:e1003618.
70. Sanders RW, Schiffner L, Master A, Kajumo F, Guo Y, Dragic T,
Moore JP, Binley JM: Variable-loop-deleted variants of the
human immunodeficiency virus type 1 envelope glycoprotein
can be stabilized by an intermolecular disulfide bond between
the gp120 and gp41 subunits. J Virol 2000, 74:5091-5100.
71. Georgiev IS, Joyce MG, Yang Y, Sastry M, Zhang B, Baxa U,
Chen RE, Druz A, Lees CR, Narpala S et al.: Single-chain soluble
BG505.SOSIP gp140 trimers as structural and antigenic
mimics of mature closed HIV-1 Env. J Virol 2015, 89:5318-5329.
72. Haynes BF, Kelsoe G, Harrison SC, Kepler TB: B-cell-lineage
immunogen design in vaccine development with HIV-1 as a
case study. Nat Biotechnol 2012, 30:423-433.
73. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM,
Yuste E, Desrosiers RC, Clark KR: Vector-mediated gene
transfer engenders long-lived neutralizing activity and
protection against SIV infection in monkeys. Nat Med 2009,
15:901-906.
74. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D:
Antibody-based protection against HIV infection by vectored
immunoprophylaxis. Nature 2012, 481:81-84.Current Opinion in Immunology 2016, 41:39–46 75.

Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M,
Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD,
Bailey CC et al.: AAV-expressed eCD4-Ig provides durable
protection from multiple SHIV challenges. Nature 2015, 519:87-91.
This study demonstrated that eCD4-Ig, a fusion of CD4I-Ig and a CCR5-
mimetic sulfopeptide expressed via an AAV vector neutralized a larger
panel of viruses than bNAbs and protected macaques against multiple
SHIV-AD8 challenges.
76. Nakamura KJ, Cerini C, Sobrera ER, Heath L, Sinkala M,
Kankasa C, Thea DM, Mullins JI, Kuhn L, Aldrovandi GM:
Coverage of primary mother-to-child HIV transmission
isolates by second-generation broadly neutralizing
antibodies. AIDS 2013, 27:337-346.
77. Russell ES, Ojeda S, Fouda GG, Meshnick SR, Montefiori D,
Permar SR, Swanstrom R: Short communication: HIV type
1 subtype C variants transmitted through the bottleneck of
breastfeeding are sensitive to new generation broadly
neutralizing antibodies directed against quaternary and CD4-
binding site epitopes. AIDS Res Hum Retroviruses 2013,
29:511-515.
78.

Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG,
Holman L, Enama ME, DeZure A, Lynch RM, Gordon I, Plummer S
et al.: Safety, pharmacokinetics and neutralization of the
broadly neutralizing HIV-1 human monoclonal antibody VRC01
in healthy adults. Clin Exp Immunol 2015, 182:289-301.
This phase I trial evaluated the bNAB, VRC01, as part of efforts to
understand whether passive transfer of bNAbs is a viable path for HIV-
1 vaccine development.
79. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P,
Enama ME, Plummer S, Holman L, Hendel CS et al.: Virologic
effects of broadly neutralizing antibody VRC01 administration
during chronic HIV-1 infection. Sci Transl Med 2015, 7 319ra206.
80. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-
Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T et al.:
Profound early control of highly pathogenic SIV by an effector
memory T-cell vaccine. Nature 2011, 473:523-527.
81. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC,
Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM
et al.: Effector memory T cell responses are associated with
protection of rhesus monkeys from mucosal simian
immunodeficiency virus challenge. Nat Med 2009, 15:293-299.
82.

Hansen SG, Piatak M, Ventura AB, Hughes CM, Gilbride RM,
Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS et al.: Immune
clearance of highly pathogenic SIV infection. Nature 2013,
502:100-104.
A RhCMV/SIV vector in rhesus macaques led to control and clearance of
a pathogenic lentiviral infection. The continuous presence of an effector
memory T-cell population maintained by CMV vectors might be a poten-
tial correlate of protection and mechanism of controlling potential HIV-1
infections.
83. Patterson LJ, Kuate S, Daltabuit-Test M, Li Q, Xiao P, McKinnon K,
DiPasquale J, Cristillo A, Venzon D, Haase A et al.: Replicating
adenovirus-simian immunodeficiency virus (SIV) vectors
efficiently prime SIV-specific systemic and mucosal immune
responses by targeting myeloid dendritic cells and persisting
in rectal macrophages, regardless of immunization route. Clin
Vaccine Immunol 2012, 19:629-637.
84. Xiao P, Patterson LJ, Kuate S, Brocca-Cofano E, Thomas MA,
Venzon D, Zhao J, DiPasquale J, Fenizia C, Lee EM et al.:
Replicating adenovirus-simian immunodeficiency virus (SIV)
recombinant priming and envelope protein boosting elicits
localized, mucosal IgA immunity in rhesus macaques
correlated with delayed acquisition following a repeated low-
dose rectal SIV(mac251) ch. J Virol 2012, 86:4644-4657.
85. Maxfield LF, Abbink P, Stephenson KE, Borducchi EN, Ng’ang’a D,
Kirilova MM, Paulino N, Boyd M, Shabram P, Ruan Q et al.:
Attenuation of replication-competent adenovirus serotype
26 vaccines by vectorization. Clin Vaccine Immunol 2015,
22:1166-1175.
86. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM,
Montefiori D, Roberts A, Buonocore L, Rose JK: An effective AIDS
vaccine based on live attenuated vesicular stomatitis virus
recombinants. Cell 2001, 106:539-549.www.sciencedirect.com
